Autoinflammatory diseases and the kidney

被引:0
作者
Mohamed Tharwat Hegazy
Ahmed Fayed
Rossana Nuzzolese
Jurgen Sota
Gaafar Ragab
机构
[1] Cairo University,Rheumatology and Clinical Immunology Unit, Internal Medicine Department
[2] Newgiza University (NGU),School of Medicine
[3] Cairo University,Nephrology Unit, Internal Medicine Department
[4] University of Siena,Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences
来源
Immunologic Research | 2023年 / 71卷
关键词
Autoinflammatory diseases (AIDs); Kidney involvement; Amyloidosis; Inflammasome; Nephropathy; Drug-induced nephrotoxicity; Interleukin-1 inhibitors;
D O I
暂无
中图分类号
学科分类号
摘要
The kidney represents an important target of systemic inflammation. Its involvement in monogenic and multifactorial autoinflammatory diseases (AIDs) vary from peculiar and relatively frequent manifestations to some rare but severe features that may end up requiring transplantation. The pathogenetic background is also very heterogeneous ranging from amyloidosis to non-amyloid related damage rooted in inflammasome activation. Kidney involvement in monogenic and polygenic AIDs may present as renal amyloidosis, IgA nephropathy, and more rarely as various forms of glomerulonephritis (GN), namely segmental glomerulosclerosis, collapsing glomerulopathy, fibrillar, or membranoproliferative GN. Vascular disorders such as thrombosis or renal aneurysms and pseudoaneurysms may be encountered in patients with Behcet’s disease. Patients with AIDs should be routinely assessed for renal involvement. Screening with urinalysis, serum creatinine, 24-h urinary protein, microhematuria, and imaging studies should be carried out for early diagnosis. Awareness of drug-induced nephrotoxicity, drug-drug interactions as well as addressing the issue of proper renal adjustment of drug doses deserve a special mention and should always be considered when dealing with patients affected by AIDs. Finally, we will explore the role of IL-1 inhibitors in AIDs patients with renal involvement. Targeting IL-1 may indeed have the potential to successfully manage kidney disease and improve long-term prognosis of AIDs patients.
引用
收藏
页码:578 / 587
页数:9
相关论文
共 93 条
[1]  
Nigrovic PA(2020)Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach J Allergy Clin Immunol. 146 925-937
[2]  
Lee PY(2018)Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases Clin Exp Rheumatol. 36 3-9
[3]  
Hoffman HM(2020)Autoinflammatory diseases in childhood, part 1: monogenic syndromes Pediatr Radiol. 50 415-430
[4]  
Lucherini OM(2019)Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases Mediators Inflamm. 2019 3293145-1018
[5]  
Navallas M(2011)The inflammasomes in kidney disease J Am Soc Nephrol. 22 1007-1440
[6]  
Gaggiano C(2009)Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview Arthritis Rheum. 61 1435-2371
[7]  
Anders HJ(2007)Natural history and outcome in systemic AA amyloidosis N Engl J Med. 356 2361-2654
[8]  
Muruve DA(2016)Systemic amyloidosis Lancet. 387 2641-48
[9]  
Obici L(2013)Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis Nephrol Dial Transplant. 29 41-896
[10]  
Lachmann HJ(1994)Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients Kidney Int. 45 890-892